Abstract
In human osteosarcoma MG63 cells, the effect of Y-24180, a presumed specific platelet-activating factor (PAF) receptor antagonist, on intracellular Ca 2+ concentration ([Ca 2+] i) and proliferation was measured by using fura-2 and tetrazolium as fluorescent dyes, respectively. Y-24180 (1–5 μM) caused a rapid and sustained [Ca 2+] i rise in a concentration-dependent manner. The [Ca 2+] i rise was inhibited by 35% by dihydropyridines or removal of extracellular Ca 2+, but was not altered by verapamil and diltiazem. In Ca 2+-free medium, thapsigargin, an inhibitor of the endoplasmic reticulum Ca 2+-ATPase, caused a monophasic [Ca 2+] i rise, after which 5 μM Y-24180 failed to increase [Ca 2+] i; conversely, depletion of Ca 2+ stores with 5 μM Y-24180 abolished thapsigargin-induced [Ca 2+] i rise. U73122, an inhibitor of phoispholipase C, inhibited histamine-induced, but not 5 μM Y-24180-induced [Ca 2+] i rise. Overnight treatment with 0.1–5 μM Y-24180 inhibited cell proliferation in a concentration-dependent manner. Together, these findings suggest that Y-24180 acts as a potent and cytotoxic Ca 2+ mobilizer in human osteosarcoma cells, by inducing both extracellular Ca 2+ influx and intracellular Ca 2+ release. Alterations in cytosolic Ca 2+ regulation may lead to interferences of various cellular functions; thus, attention should be exercised in using Y-24180 as a selective PAF receptor antagonist.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
